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While target-based small-molecule discovery has taken centre-stage in the pharmaceutical industry, there are many cancer-promoting
proteins not easily addressed with a traditional target-based screening approach. In order to address this problem, as well as to
identify modulators of biological states in the absence of knowing the protein target of the state switch, alternative phenotypic
screening approaches, such as gene expression-based and high-content imaging, have been developed. With this renewed interest in
phenotypic screening, however, comes the challenge of identifying the binding protein target(s) of small-molecule hits. Emerging
technologies have the potential to improve the process of target identification. In this review, we discuss the application of genomic
(gene expression-based), genetic (short hairpin RNA and open reading frame screening), and proteomic approaches to protein
target identification.
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The last decade has seen dramatic change in approaches to
biomedical discovery through the advent of massively parallel
sequencing technologies to sequence genomes, the ability to
characterise the transcriptome and an improved ability to evaluate
the proteome. Nowhere, perhaps, has this change been more
readily apparent than in cancer-based discovery where cancer-
promoting targets are being identified at an ever-increasing
pace. An important challenge now is how to best exploit these
new capabilities for therapeutic benefit. In this review, we focus on
one area of increasing need: the development of new approaches to
identify the direct protein-binding targets of small molecules.
Specifically, we focus on the application of chemical genomics,
genetic-based screening, and chemical proteomics to identify the
critical protein targets of drugs and discuss illustrative examples
of each (Figure 1).
ADVANCES IN PHENOTYPE-BASED SCREENING:
NEW CHEMICAL DISCOVERIES BUT NEW
CHALLENGES
With the demonstration of clinical efficacy for targeted agents,
such as all-trans-retinoic acid in PML-RARa-rearranged acute
promyelocytic leukaemia, trastuzumab treatment for HER2-
amplified breast cancer, and imatinib therapy for BCR–ABL-
rearranged chronic myelogenous leukaemia, there has been a sea
change in cancer-based drug discovery (Capdeville et al, 2002;
Sanz, 2006; Hudis, 2007; Lo-Coco et al, 2008). Currently, the
majority of cancer drug discovery efforts in the pharmaceutical
industry are target based. Although there is a strong rationale for
target-based therapies, such as improved tumour cell specificity
and decreased normal cell toxicity, there are limitations to target-
based screening approaches. First, target-based screening typically
involves ex cellulo assays, which may not recapitulate cellular
complexity. Second, many validated cancer targets, such as
transcription factor abnormalities, have been difficult to ‘drug’
using standard target-based screening. High-throughput assays
to measure DNA–protein or protein–protein interactions have
proven difficult to develop. Third, there are many desired state
changes (e.g., differentiation) for which a validated protein target
has not yet been identified. In response to these challenges, new
approaches to phenotypic screening have been developed. One
area of progress has been the application of high-content imaging
to enable fine-grained phenotypic measurements from single cells
and kinetic studies of living cells in response to small-molecule
perturbation (Giuliano et al, 1997, 2003; Carpenter, 2007).
Another new approach to phenotypic screening leverages
the assessment of gene expression signatures as surrogates for
different biological states. One implementation of this approach
is gene expression-based high-throughput screening (GE-HTS)
(Stegmaier et al, 2004). Genome-wide expression-based micro-
arrays are used to define a set of genes distinguishing two different
biological states, and the signature is refined to include up to 500
genes, which can be measured in 384-well format. One successful
detection system has used ligation-mediated amplification and a
fluorescent bead-based technology (Peck et al, 2006), although one
can envision the implementation of other technologies such as
Nanostring or RNAseq. Using this method, a small-molecule
library is screened for chemicals that induce a change from
the ‘state A’ expression signature to that of the ‘state B’. Gene
expression-based high-throughput screening has been applied to
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tion, modulators of transcription factor abnormalities, inducers of
fetal haemoglobin, inhibitors of androgen receptor activation,
and modulators of mitochondrial oxidative-phosphorylation
physiology (Stegmaier et al, 2005; Hieronymus et al, 2006;
Wagner et al, 2008; Corsello et al, 2009; Hahn et al, 2009; Bradner
et al, 2010).
Although alternative screening approaches may address some of
the current challenges in small-molecule discovery, such as
targeting intractable cancer-promoting proteins, or identifying
modulators of complex state switches in the absence of target
knowledge, as in the case of more traditional phenotypic-based
screening, they engender the problem of identifying the protein
target of the small-molecule hit. Target identification is critical to
follow-up medicinal chemistry efforts, to identify predictors of
response to therapy, and to understand mechanisms of resistance.
Affinity chromatography is one standard approach used to identify
the protein targets of small molecules. This approach is limited,
however, by the requirement of small molecules with both high
affinities for their targets and for high expression of the protein
target of interest. Moreover, the generation of affinity matrices,
which immobilise a derivative of the small molecule but also retain
the original activity of the molecule, often require significant
optimisation. New genomic, genetic, and proteomic approaches,
discussed below, should improve the pipeline for protein
target identification of chemical hits emerging from cell-based,
phenotypic screens.
GENE EXPRESSION-BASED SOLUTIONS TO PROTEIN
TARGET IDENTIFICATION
Transcriptional profiling of chemically or genetically manipulated
cellular systems can be used to connect a compound of interest
with its protein target. One of the first proof-of-concept studies
was performed in Saccharomyces cerevisiae (Hughes et al, 2000).
Hughes et al generated a compendium of expression profiles of
genetic mutations or drug treatments affecting Saccharomyces
cerevisiae cells. They demonstrated that different mutants or
chemical treatments affecting similar cellular processes induce
similar expression profiles, suggesting that the compendium could
be used to characterise the mechanism of pharmacological
perturbations by using gene expression pattern-recognition
algorithms.
Expanding on this idea, Lamb et al developed the Connectivity
Map (C-Map), the first mammalian compendium of chemically
perturbed transcriptional profiles, as an in silico tool for signature-
based small-molecule and target discovery (Lamb et al, 2006;
Lamb, 2007; Palchaudhuri and Hergenrother, 2011). The C-Map is
a reference collection of genome-wide transcriptional expression
data from cultured human cancer cells (breast cancer MCF7,
prostate cancer PC3, leukaemia HL60, and melanoma SKMEL5 cell
lines) profiled on the Affymetrix (Santa Clara, CA, USA) high-
throughput array platform. In its first public release (Build 01),
the C-Map profiled 164 bioactive small molecules at 6h, with most
compounds profiled at 10mM. Each treatment instance was defined
relative to control cells treated with vehicle and grown in the same
plate. For each treatment in the C-Map, the 22000 genes were rank
ordered based on their differential expression relative to the batch
control. The C-Map user defines a query signature associated with
a particular condition of interest, which is then assessed for
connection with each of the profiled compounds in the reference
collection using a rank-based pattern matching algorithm. The
C-Map is available on a publicly accessible website www.broad
institute.org/cmap, which also includes meta-data (chemical name,
concentration, cell line, and batch) and analytical tools, provides
links for each compound to a vendor and to Chembank (a database
for structures and synonyms), and displays the Anatomical
Therapeutic Chemical classification assigned by the World Health
Organisation to drug substances. A new users’ tutorial is available
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Figure 1 Approaches to target identification. One of the challenges of phenotypic screening is the identification of the protein target(s) of the compound
hit. Although an affinity chromatography-based approach was once among the only solutions to this challenge, new chemical, proteomic, gene expression,
and shRNA screening-based approaches are increasing the armamentarium of tools for identifying the mechanism of action of compounds emerging from
phenotypic screens.
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to take users through the basic steps in executing and interpreting
a C-Map query. It also includes definitions of key C-Map-related
terminology. The second build of the C-Map (Build 02) is publicly
available and includes the profiling of 1309 discrete small
molecules with raw data cel files available for download enabling
user data-mining of the full compendium of expression profiles.
The next iterations of C-Map will also include genetic perturba-
tion, such as short hairpin RNA (shRNA) and open reading
frames (ORFs).
To illustrate the potential of C-Map to connect a small molecule
with its protein target, we first discuss a study, which integrates a
GE-HTS screen for lead molecule discovery with the C-Map for
protein target identification. Hieronymus et al (2006) sought
to identify chemical modulators of androgen receptor signalling in
prostate cancer. Given the paucity of available approaches to
identify modulators of androgen receptor signalling, a GE-HTS
approach was used. First, a gene expression signature was defined
by identifying the genes whose expression distinguishes the
androgen activation versus deprivation states using Affymetrix
expression microarray profiling and adapted to the GE-HTS assay.
A total of 2500 compounds were then screened for the ability to
modulate a 27-gene signature in the presence of synthetic
androgen in the prostate cancer cell line LNCaP. The natural
products celastrol and gedunin were identified and confirmed to
strongly induce the androgen deprivation signature. As a result
of the lack of knowledge of the protein targets of gedunin and
celastrol, the investigators leveraged the C-Map to identify
their mechanism of action. Genome-wide expression profiles of
gedunin- and celastrol-treated LNCaP cells were generated and
used to query the C-Map. The gedunin and celastrol profiles were
strongly connected to the gene expression profiles of multiple,
structurally distinct HSP90 inhibitors leading to the hypothesis
that these agents were themselves HSP90 inhibitors. Indeed, both
molecules were demonstrated to inhibit HSP90 activity and HSP90
clients by a mechanism that is distinct from that of existing HSP90
ATP-binding pocket inhibitors.
Multiple examples now exist of the application of the C-Map to
connect small-molecule modulators with their mechanisms of
action and/or protein targets. Two recent examples connect small-
molecule hits emerging from independent cancer cell-based
screens with intracellular iron depletion (Coombs et al, 2011;
Gullbo et al, 2011). Gullbo et al (2011) screened 3000 compounds
in primary ovarian carcinoma cultures for those inducing
cytotoxicity and identified the compound CD02750 (VLX50) and
structurally related molecules as top hits. After confirming broad
spectrum activity in a panel of patient-derived cancer cells, a drug-
specific signature was identified using genome-wide expression
profiling and used to query the C-Map. The VLX50 signature
showed the strongest correlation with several iron chelators and
also showed a significant enrichment with genes induced by
hypoxia and hypoxia-inducible factor 1 a (HIF-1a) by gene set
enrichment analysis (GSEA), also consistent with iron chelation
(Subramanian et al, 2005). The investigators experimentally
confirmed that VLX50 decreases iron concentration in MCF-7 cell
cultures and that VLX50 drives the expression of genes associated
with HIF-1 signalling.
In an independent screen for compounds that inhibits Wnt/b-
catenin pathway using a cell-based luciferase reporter, Coombs
et al (2011) also connected the small-molecule candidates
emerging from their screen to iron chelation via the C-Map. From
50000 synthetic compounds, a family of 8-hydroxyquinolone
derivatives was identified. The lead compound N-((8-hydroxy-
7-quinolinyl)(4-methylphenyl)methyl)benzamide (HQBA) was
demonstrated to inhibit growth in both Wnt-initiated and
Wnt/b-catenin-dependent MMTV-Wnt1-transgenic mice and in
MMTV-PyMT mice with no evidence of activation of the Wnt-
catenin pathway. After failed attempts to identify a direct binding
partner of HQBA with an unmodified and a photocrosslinker-
containing analogue of HQBA, genome-wide expression profiles of
HQBA-treated MCF7 cells connected the non-structurally related
iron chelators ciclopirox and deferoxamine to the HQBA signature
in C-Map. The investigators next demonstrated that chelation
of intracellular iron, specifically Fe
2þ, is responsible for the
biological effects of HQBA; premixing of HQBA with Fe
2þ
completely abrogated its toxicity.
A fourth recent C-Map example is provided by Shaw et al
(2011). Here, the investigators performed a high-throughput,
synthetic lethal screen to identify small molecules that selectively
kill mouse embryonic fibroblast (MEFs) expressing oncogenic
K-ras. From a collection of 450000 small molecules, tolperisone
was identified as highly selective against K-ras mutant cells
compared with wild type. Lanperisone, a tolperisone derivative,
demonstrated even more potent activity on K-ras
G212 mutant cells
and was subsequently selected for additional studies. In order to
address compound mechanism of action, a lanperisone gene
expression signature was derived from MEFs treated for 6h.
As in the prior two examples discussed above, this drug signature
was connected to hypoxia and the HIFs by GSEA. However, while
HIFs were induced by lanperisone, they did not have a functional
role in the selective killing of K-ras mutant cells. In this case, a
C-Map query identified numerous small molecules that induce
oxidative stress including parthenolide, lomustine, geldanamycin,
and 15-d-prostaglandin J2. Induction of reactive oxygen species
was then confirmed as the mechanism of lanperisone-induced
K-ras selective cytotoxicity.
Although the above studies demonstrate the application of
C-Map to connect small molecules with their pathway mechanism
of action or direct protein-binding target, the C-Map has also been
used for other applications, such as to identify synergistic
combinations of compounds as reported by Hassane et al (2010).
First, the investigators identified parthenolide as a small molecule
with activity in both the acute myeloid leukaemia (AML)-initiating
cell and the bulk population of AML cells by both inhibiting NF-kB
and inducing oxidative stress (Guzman et al, 2007). From genome-
wide expression profiling of parthenolide-treated AML cells, the
investigators noted that a cytoprotective response was induced
through activation of the Nrf2 pathway (Hassane et al, 2008). They
next used the C-Map to identify compounds negatively correlated
with a 150-gene parthenolide signature hypothesising that such
compounds might counteract the cytoprotective response signa-
ture induction and thus diminish the cytoprotective response
induced by parthenolide (Hassane et al, 2010). PI3K and mTOR
inhibitors were among the molecules negatively connected to
the parthenolide signature leading to the hypothesis that the
PI3K/mTOR pathway is activated in response to parthenolide
treatment. The investigators then demonstrated that the PI3K/
mTOR pathway is indeed activated by parthenolide using a
biochemical approach and that there is synergism with PI3K and
mTOR inhibitors in combination with parthenolide in vitro and
with the pharmacologically superior analogue dimethyl-amino-
parthenolide in primary human AML orthotopic models.
In summary, this work demonstrates the power of chemical
genomics to enable discovery of modulators of a complex cancer
phenotype, identification of the mechanism of action of the small-
molecule hits, and nomination of synergistic combinations of
compounds. Although this approach is potentially quite powerful,
there are limitations. First, the expression readout may be far
downstream of the actual binding target and may lead to the
pathway of action but not the direct protein target of the molecule.
Second, the current build of the C-Map is restricted to a limited
number of cell lines and compound doses. Cell context
will undoubtedly be important in some cases limiting the ability
to identify targets, and the compound doses chosen in
C-Map might miss some interactions and be clinically irrelevant
in others.
Drug target identification
G Roti and K Stegmaier
256
British Journal of Cancer (2012) 106(2), 254–261 & 2012 Cancer Research UKGENETIC SCREENING FOR PROTEIN TARGET
IDENTIFICATION
Sequencing the human genome and the genome of many model
organisms has enabled new opportunity with genetic screening for
the identification of protein targets of small-molecule therapeutics.
As in the case of the application of gene expression profiling
to protein target identification, many of the first proof-of-
concept genetic screens were performed in the model organism
Saccharomyces cerevisiae. An initial study by Giaever et al (1999)
demonstrated that yeast strains with heterozygous deletion of drug
targets can result in sensitisation to the drug target of interest in
comparison with the diploid strain (haploinsufficiency profiling).
The investigators later scaled this approach to the evaluation of 10
small molecules in 80 genome-wide experiments using a collection
of molecularly barcoded heterozygous deletion strains (Giaever
et al, 2004). Relative abundance of each strain was quantified by
amplification of the molecular barcodes from genomic DNA and
hybridised to oligonucleotide microarrays containing the com-
plementary barcodes. For many of the compounds evaluated, the
most sensitive heterozygous strain carried a deletion of the well
validated, direct binding protein target of the molecule. In a
publication by Lum et al (2004), a genome-wide pool of tagged
heterozygotes was used to assess the effects of 78 compounds in
Saccharomyces cerevisiae. A high-density oligonucleotide array
with a two-colour labelling strategy was used to monitor growth
rates. In this study, the investigators successfully identified many
well-validated targets of small molecules, such as those involving
compounds targeting the ergosterol pathway: lovastatin (HMG1),
terbinafine (ERG1), and clotrimazole (ERG11). Moreover, they
identified new potential targets such as lanosterol synthase as a
target of the antianginal drug, molsidomine, and the ribosomal
RNA processing exosome as a potential target of the anti-
neoplastic agent 5-fluorouracil.
A next important step was the extension of genetic screening to
mammalian systems. The production of libraries of DNA-based
vectors encoding shRNA targeting most known genes in the
human genome now enable genome-wide loss-of-function screens
in mammalian cells; furthermore, the generation of libraries of
ORFs enable gain-of-function screens. A publication from Burgess
et al (2008) serves as an example of using a pooled RNAi screening
strategy both in vitro and in vivo to explore the genetic basis of the
heterogeneous response to topoisomerase poisons. An in vitro
screen was performed using retrovirally encoded shRNAs targeting
a set of 100 known, or putative, cancer-related genes. The shRNA-
containing vectors were transduced into the p19
ARF /  Em-Myc
murine lymphoma cell line, and infected cells were treated with
doxorubicin at doses that typically kill 70–95% of the cells within
24h. shRNAs enriched after doxorubicin treatment were identified,
including shRNAs targeting p53, CHK2, and one of the known
targets of doxorubicin, TOP2A. TOP2A-directed shRNAs were also
confirmed to confer resistance to doxorubicin in vivo. Topoi-
somerase II inhibitors, such as doxorubicin, increase the steady
state of the topoisomerase II-DNA cleavage complexes and thus
poison the cell with excess complex formation leading to DNA
double-strand breaks and apoptosis. Hence, downregulation of
TOP2A expression would be expected to confer doxorubicin
resistance rather than increase sensitivity. Moreover, the investi-
gators demonstrated that shRNAs directed against TOP2A cause
resistance to another topoisomerase 2 inhibitor, etoposide, but not
to the topoisomerase 1 inhibitor camptothecin. In contrast, TOP1-
directed shRNAs conferred resistance to camptothecin in vitro and
in vivo, and unexpectedly, TOP1 shRNAs enhanced sensitivity to
topoisomerase 2 inhibitors. This study highlights the potential of
shRNA-based screening to identify drug targets and determinants
of chemotherapy response in mammalian cells.
Parallel to the development of loss-of-function screens,
overexpression strategies have been pursued to identify relevant
targets of small molecules. Among the first examples of a large-
scale overexpression screen for target identification in mammalian
cells was a study reported by Luesch et al (2006). A total of 27000
expression cDNAs were screened for suppression of the anti-
proliferative effect of the cyanobacteria metabolite, aprotoxin A, in
the human osteosarcoma cell line U20S. Several cDNA plasmids
expressing FGFR protein variants partially rescued the induction
of cell cycle arrest and apoptosis induced by aprotoxin A, and
phosphorylation of STAT3, a downstream target of FGFR, was
inhibited by aprotoxin A. An inverse correlation of FGFR
expression with aprotoxin A sensitivity in a panel of cancer cell
lines was also observed, suggesting that a highly expressed FGFR
pathway is one mechanism of resistance to aprotoxin A in cancer
cell lines. There was no inhibition of the kinase activities of
FGFR1–FGFR4 by aprotoxin A in biochemical assays, however,
and the precise target of apratoxin A in the FGFR pathway remains
to be elucidated. Although in this case, a chemogenomic approach
did not identify the direct binding target of the small molecule,
it enabled identification of a pathway of importance to the
mechanism of action of the drug.
More recently, investigators have begun to integrate multiple
genetic screens for protein target identification. Hoon et al (2008)
combined both loss- and gain-of-function chemogenomic strate-
gies for target identification in yeast. In this screening platform,
three different yeast pools were interrogated with a single TAG4
array: a homozygous deletion pool, a heterozygous deletion pool,
and a pool of genomic library transformants, each treated with a
compound of interest. First, a panel of eight reference compounds
was evaluated. From the intersection of deletion sensitivity
profiling (sensitivity when deleted) and multi-copy suppression
profiling (resistance when overexpressed), known targets of
methotrexate (DFR1), fluconazole (ERG11), and rapamycin
(TOR2) were identified. Next, the investigators extended screening
to 188 synthetic chemicals and identified new candidate targets for
these molecules. The intersection of deletion sensitivity and multi-
copy suppression profiling refined the list of potential targets for
subsequent validation studies.
Although genetic screens are another important approach
toward target identification, there are potential limitations. First,
they are only as good as the library screened. Less comprehensive
libraries may miss the critical target of the compound of interest
and even comprehensive libraries may not have efficient shRNAs
against all of the represented genes or all of the cDNAs expressing
fully functional proteins. In addition, shRNAs are well known to
have off-target effects, which may confound interpretation of the
results and massive overexpression of a gene may not reflect target
binding under physiological conditions. Finally, these genetic
screens are also limited by one’s ability to either infect or transfect
the cells of interest.
CHEMICAL PROTEOMIC APPROACHES TO PROTEIN
TARGET IDENTIFICATION
In addition to new chemical genomic and genetic approaches to
connect small molecules with their protein targets, chemical
proteomic approaches have the potential to facilitate protein target
identification by cataloguing proteome-wide small molecule–
protein interactions using drug affinity chromatography coupled
to mass spectrometry (MS) and computational analysis (Rix and
Superti-Furga, 2009). In a compound-centric approach to chemical
proteomics, the molecule of interest is immobilised on a matrix
such that its activity is retained. The cell lysate of interest is then
incubated with the affinity matrix and washed before elution. The
eluted proteins are then processed by SDS–PAGE or a gel-free
approach, digested, and then identified and quantified by MS. One
strength of chemical proteomics is the ability to probe the entire
proteome, rather than a limited panel of recombinant proteins,
Drug target identification
G Roti and K Stegmaier
257
British Journal of Cancer (2012) 106(2), 254–261 & 2012 Cancer Research UKand that the small molecules encounter these proteins in their
natural state and environment. Another strength is that chemical
proteomics can be performed in any cell type or tissue of interest.
Disadvantages to this approach are that there is a need for a
relatively high quantity of cellular material and that the lysis
protocol used may not capture all proteins equally well,
particularly membrane-bound proteins. Moreover, a high back-
ground level can be created by very abundant proteins or proteins
prone to interacting with hydrophobic or charged surfaces.
Another challenge is that the identification of binding proteins is
semi-quantitative and does not generally provide a tight correla-
tion with half-maximal inhibitory values.
One important advance made in chemical proteomics has been
the improvement in quantification via the application of methods
such as stable isotope labelling. One successful approach is stable
isotope labelling with amino acids in cell culture (SILAC), a
metabolic incorporation of a label (e.g., deuterium,
13C,
15N) into
proteins for MS-based quantitative proteomics (Ong et al, 2002).
This method exploits the ability of live cells to incorporate labelled
amino acids through media supplementation. The newly synthe-
sised proteins will incorporate either the ‘light,’ natural isotope
abundance forms, or the ‘heavy,’
13C,
15N-bearing versions of
arginine and lysine amino acids making it possible to monitor
quantitative differences at the protein level between conditions.
Protein lysates from ‘heavy’ or ‘light’ cultures are incubated
with small-molecule-loaded beads versus control beads or small-
molecule-loaded beads versus small-molecule-loaded beads and
soluble small-molecule competitors. Proteins interacting directly
with small molecules are discriminated from nonspecific interac-
tion because of the enrichment in one state over the other and
identified by differential ratios in the target pull-down sample
(Ong et al, 2009).
The approach of combining SILAC with small-molecule affinity
enrichment was tested by Ong et al (2009) to identify targets of
kinase inhibitors and immunophilin binders. The investigators
compared two experimental designs: one used a bead control and
the second used a soluble competition for SILAC target identifica-
tion. In the first design, the relative abundance of proteins from
affinity pull-downs with two different chemically modified
bead matrices was tested: small-molecule-loaded beads versus
ethanol-loaded beads. In the soluble competition experiment,
small-molecule-loaded beads were used in both the heavy and light
affinity pull-downs, but in one condition, an excess of small
molecule was added to compete for target proteins (Figure 2).
To evaluate these approaches, the investigators tested two
independent classes of small molecules: kinase inhibitors
(R0-31-7549, SB202190, and K252a) and immunophilin binders
(AP1497, Pro-AP1497, AP1780, and Pro-AP1780). The investiga-
tors concluded that SILAC with small-molecule affinity enrichment
improves sensitivity and specificity of unbiased affinity purifica-
tion-based target identification and that the soluble competition
experimental approach is the preferred method in SILAC target
identification. In the kinase inhibitor experiments, known protein
targets, associated protein complexes, as well as proteins with
related biology were successfully identified. In the immunophilin
experiments, known targets, such as members of the FKBP family,
were identified, and the binding affinities of the FKBP family
members with different immunophilins were characterised.
Furthermore, methylthioadenosine phosphorylase was identified
and validated as a new interactor with all members of the
immunophilin series. Although the bead control successfully
identified target proteins, it also produced a list of moderate to
highly abundant proteins with weak but differential binding to the
small molecule. In contrast, the use of the soluble competition
design yielded much greater specificity and was largely indepen-
dent of protein abundance. Moreover, because it uses the same
small-molecule affinity matrix in both the control and experiment
samples, it circumvents the challenge of selecting an appropriate
control matrix.
Although we have focused on SILAC in this review, other stable
isotope labelling-based quantitative MS chemical proteomic
approaches are in use. Two examples include iTRAQ (isobaric
tags for relative and absolute quantification) and ICAT (isotope-
coded affinity tag) (Gygi et al, 1999; Bantscheff et al, 2007a,b; Rix
and Superti-Furga, 2009). The iTRAQ technology is a gel-free
approach utilising isobaric reagents to label the primary amines of
peptides and proteins. The iTRAQ can be implemented after cell or
tissue lysis and thus can be used to quantify proteins in any
biological system. As such, it is not limited to only those systems
that can accommodate incorporation of stable isotopes during cell
culture, such as in SILAC. Similarly, ICAT is a gel-free approach
that can be used to quantify proteins in any biological system. This
approach utilises a chemical reagent that consists of a reactive
group for labelling cysteines, an isotopic linker region, and a biotin
affinity moiety. The ICAT approach, however, will only quantify
proteins with cysteines.
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Figure 2 Stable isotope labelling with amino acids in cell culture schema. Adapted from (Ong et al, 2009). Two cell populations are grown in medium
containing light (blue) or heavy labelled amino acids (red). Protein lysates from the two cell populations are then harvested and incubated with small-
molecule-loaded beads or small-molecule-loaded beads and excess of free small molecule to competitively displace target proteins in one of the lysate
mixtures. Beads from both lysates are then washed, combined, and boiled. Proteins that remain bound to the immobilised small molecule are eluted,
separated by SDS–PAGE, identified and quantified with MS, and SILAC ratios determined. Proteins interacting directly with the small molecule or by
secondary interaction with the small molecule (S) will be enriched in the heavy state and will be identified with differential ratios. Nonspecific interactions
(NS) will be enriched equally in the light and the heavy states and have ratios closer to 1.
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approaches, however, is the need to derivatise the small molecule
for affinity purification with the requirements that the molecule
contains a domain, which can be derivatised, that the bioactivity is
not altered by the derivitisation, and that the matrix does not
impede the binding of the drug to the protein. Alternative
approaches to chemical synthesis, such as diversity-oriented
synthesis (DOS), are being employed to address this challenge,
in part. Here, the goal is to generate collections of molecules with
the structural and stereochemical diversity of natural products,
which are poised for optimisation and contain functional handles
for the generation of affinity reagents (Wang et al, 2008). Some
successful applications of DOS chemistry led to the identification
of the compound robotnikinin as a binder of Sonic Hedgehog and
inhibitor of its signalling pathway (Stanton et al, 2009), the novel
HDAC6 inhibitor tubacin (Haggarty et al, 2003), haptamide A as a
modulator of Hap3p a subunit of the yeast Hap2/3/4/5p transcrip-
tion factor complex (Koehler et al, 2003), and uretupamine as an
activator of a glucose-sensitive transcriptional pathway down-
stream of Ure2p (Kuruvilla et al, 2002).
Alternative chemical proteomics approaches to protein target
identification of small molecules, which do not rely on affinity
reagents are also under development. For example, SPROX
(stability of proteins from rates of oxidation) combines a chemical
modification- and MS-based method with MS-based proteomics to
measure the thermodynamic stability of protein–ligand complexes
(West et al, 2010). The SPROX approach makes thermodynamic
measurements of protein-folding reactions to detect target protein
drug interactions and uses methionine oxidation levels, in complex
protein mixtures, to measure transition midpoints consistent with
stabilisation. As a proof-of-principle experiment, West et al (2010)
investigated the protein targets of the immunosuppressive drug
cyclosporine A (CsA) in yeast cell lysates. The investigators
identified 10 hits that interact with CsA. Two known targets were
identified: the direct target cyclophilin A and the indirect target
UDP-Glucose-4-Epimerase, as well as 8 previously unreported
targets, including proteins involved in glucose metabolism.
Although the ability to identify potential direct and indirect drug
targets in the absence of an affinity reagent is an advantage, there
are disadvantages to the SPROX approach. First, the target must
contain a methionine-containing peptide in the domain of the
target protein, which has its thermodynamic properties modulated
by the small-molecule interaction. Second, there must be suffi-
ciently high protein and ligand concentration to generate a
measurable transition midpoint shift. Moreover, the oxidative
reaction used to interrogate the folding/unfolding of the proteins
might itself alter the protein-folding and ligand-binding properties.
Another chemical proteomic approach to target identification is
DARTS (drugs affinity responsive target stability), which exploits
the reduction in the protease susceptibility of the target protein on
drug binding (Lomenick et al, 2009). The DARTS strategy is based
on the notion that the binding of a drug to a target protein leads to
protein stabilisation or to masking of a protease recognition site,
making the protein less susceptible to protease activity. DARTS
uses an affinity-based chromatography method that selectively
enriches from protein mixtures target proteins that are rendered
protease-resistant on small-molecule ligand interaction. In a
proof-of-concept experiment, Lomenick et al (2009) confirmed
by the DARTS approach the previously reported target of several
small molecules, such as the immunophilin FKBP12 for the
immunosuppressants FK506 and rapamacyin and the human
elongation factor-1a for the anticancer marine natural product
didemnin B. Furthermore, the investigators validated their
approach by identifying a new putative target in the yeast cell
lysate of the natural product resveratrol, eIF4A. As in SPROX,
one major advantage of the DARTS approach is that it does not
require derivitising the small molecule; it is not limited by
synthetic chemistry and can be applied to any small molecule of
interest or natural product. Second, as in SPROX, and unlike
cell-based target identification, the DARTS approach is indepen-
dent of the phenotypic effect of the drug on the system and can
thus be performed using any cell type. Like all approaches,
however, there are limitations. The binding affinity of the drug to
its target might be a limiting feature in DARTS. Second, some
proteins might be particularly refractory to protease digestion.
Third, drug binding might change the protease susceptibility of
non-target proteins.
INTEGRATING MULTIPLE APPROACHES FOR
TARGET IDENTIFICATION
Each approach toward target identification has both advantages
and limitations as discussed above. To increase the likelihood of
correctly identifying target proteins, one might integrate multiple
approaches. We employed such a strategy to explore the off-target
activities of epidermal growth factor receptor (EGFR) inhibitors in
AML (Stegmaier et al, 2005). Using GE-HTS, we identified EGFR
inhibitors as small-molecule inducers of AML differentiation in
AML cell lines and primary patient blasts. However, we were
unable to identify EGFR expression in the cell lines responding to
these EGFR inhibitors suggesting that in these cell lines, the
activity of the EGFR inhibitors was off-target. In order to identify
candidate targets of these compounds, we integrated a proteomic
and genetic screening approach. A proteomic approach was used
with peptide immunoprecipitation-HPLC-MS to identify candidate
targets with differential phosphorylation in EGFR inhibitor-treated
AML compared with a vehicle control. Spleen tyrosine kinase
(SYK), a cytoplasmic tyrosine kinase critical in B-cell development
and hematopoietic signalling, was identified as a candidate target.
To increase the confidence in hits identified in the proteomic
screen, we intersected a high-throughput, lenti-virally delivered
shRNA screen designed against the human kinome, which used an
AML differentiation signature readout. One of the top scoring
shRNAs targeted SYK. Subsequent validation studies confirmed
that loss of SYK with pharmacological and genetic inhibition
impaired AML cell viability and promoted AML cell differentiation
in vitro. Moreover, the orally available SYK inhibitor, fostamatinib,
demonstrated activity in three in vivo models of AML, identifying
SYK as a new potential druggable protein for AML therapy (Hahn
et al, 2009). This work demonstrated the power of integrating
multiple new approaches to identify the protein target of small-
molecule hits emerging from chemical genomic screens.
A similar approach of combining chemogenomics with targeted
shRNA screening was taken to identify novel therapeutics for
sickle cell disease. (Bradner et al, 2010) Here, the investigators
developed a GE-HTS assay to measure the expression of globin
genes during erythroid differentiation. They next performed a
small-molecule library screen and identified histone deacetylase
(HDAC) inhibitors as increasing the g/b ratio. To confirm the
dependency of the induced phenotype on HDAC inhibition and to
further delineate the critical HDACs, the investigators genetically
targeted individual HDAC transcripts with shRNAs. Histone
deacetylase-1 and 2 were validated as potential targets mediating
the induction of fetal haemoglobin in primary erythroid cells.
CONCLUSION
The development of new approaches to small-molecule library
screening enables opportunity for compound discovery to target
pharmacologically intractable proteins, such as transcription
factors, and to modulate biological processes in the absence of
knowledge of the target critical to the state switch. With the
parallel development of alternative strategies for protein target
identification, including chemical genomic, genetic, and chemical
proteomic, the potential to understand both the on-target
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as to predict the potential toxicities becomes feasible. The efficient
execution of these projects involves significant infrastructure and
expertise in multiple disciplines including chemistry, genomics,
proteomics, and bioinformatics. Only with collaborative efforts
across academic institutions and industry will the potential of
these approaches be fully realised and translated to more effective
therapies for patients with cancer.
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